Neck lift after nonsurgical neck treatment
- O'Daniel and Patton 2026, 180 neck lifts in 2023: 123 (68%) had prior neck treatment, surgical or nonsurgical (PMID 40712094).
- Prior treatments in that series: chemolipolysis (Kybella), cryolipolysis (CoolSculpting), radiofrequency-assisted lipolysis (FaceTite, Morpheus8, SmartLipo, Ultherapy, Profound), and suture suspension (MyEllevate, PDO threads) (PMID 40712094).
- Intraoperative findings after nonsurgical treatment: fibrosis, loss of tissue planes, rigid platysma and deep fascia, unpredictable fat distribution (PMID 40712094).
- Deep cervicoplasty with subplatysmal management was needed in 94%; operative time increased in all; nearly all had postoperative contour irregularities from destroyed supraplatysmal fat and platysma; no major complications (PMID 40712094).
- Cervantes, O'Daniel, L. Auersvald, Pacifico, A. Auersvald et al 2026: facelift in patients with prior dermal fillers and energy-based device treatments, challenges and strategy (PMID 42321446).
- Deoxycholic acid injections and later neck surgery (PMID 31860219).
Facelift after fillers, threads and devices
- Facelift with removal of permanent filler, 50 patients: preoperative asymmetry 82%, disfiguring edema 26%; 62% satisfied (PMID 36110395).
- Patients under 50 before facelift, 157 surveyed: 32% had injectables (mean 7 rounds), 16% laser resurfacing, 10% energy-based tightening; mean spend $7,000; felt 4 years younger after nonsurgical treatment and 8 years after facelift (PMID 27965217).
- Thread lift meta-analysis, 26 studies, 2,827 patients: swelling 34%, ecchymosis 26%, visible or palpable threads 10%, dimpling 7% (PMID 41988336).
- Thread-lift complications in the FDA MAUDE database 2003-2023 (PMID 37594003).
- Skin to superficial fascia depth measured for device targeting: 3.71-4.82 mm by region (PMID 30882511).
GLP-1 receptor agonists and the face
- CT/MR in 20 patients on GLP-1 agonists (mean 11.0 kg lost): median midface volume loss 9.0%; superficial 11.0%, deep 7.0%; about 7% per 10 kg lost; superficial loss correlated with weight loss (PMID 40407186).
- "Ozempic face" review, 2023: facial volume depletion, wrinkles and sagging with rapid weight loss; consider stopping before general anesthesia because of delayed gastric emptying (PMID 37541662).
- Mechanism review 2024: loss of dermal and subcutaneous white fat and altered adipose-derived stem cell function (PMID 38874170).
- Systematic review 2025, 23 plastic surgery articles; online searches for "Ozempic face" linked to rising searches for fillers and plastic surgeons (PMID 40626110).
- Anatomy review 2026: superficial compartment deflation, loss of deep support, skeletal resorption and skin laxity after medical weight loss (PMID 42210888).
- Fat grafting in GLP-1 users: no clinical or preclinical study has measured graft survival; mechanisms (adipocyte browning, lipolysis, stem cell shift) are hypothesized to reduce take (PMID 42219269).
- Biostimulator case series: hyperdilute calcium hydroxylapatite in 4 GLP-1 users losing 9.2% body weight; facial metrics stable or improved at 6 months (PMID 41127050).
- PLLA after facelift: significant postoperative weight loss listed as an indication (PMID 35662905).
Facelift after major weight loss
- Massive weight loss faces show deflation and inelastic skin; wide undermining is the critical step (PMID 31514808).
- Modifications: wide face and neck undermining, extended postauricular incisions, SMAS and platysma treatment, deep malar fat transfer (PMID 30447822).
Perioperative GLP-1 management
- Multisociety guidance 2024 (AGA, ASMBS, ASA, ISPCOP, SAGES) (PMID 39482213).
- GLP-1 therapy may be continued before surgery in patients without elevated risk of delayed gastric emptying and aspiration (https://www.ebi.ac.uk/europepmc/webservices/rest/PMC11666732/fullTextXML).
- If held: day of surgery for daily drugs, one week before for weekly drugs, following the original ASA guidance (https://www.ebi.ac.uk/europepmc/webservices/rest/PMC11666732/fullTextXML).
- A liquid diet for at least 24 hours before surgery can be used when delayed gastric emptying is a concern (https://www.ebi.ac.uk/europepmc/webservices/rest/PMC11666732/fullTextXML).
Glossary
- GLP-1 receptor agonist (GLP-1 RA): drug class including semaglutide and tirzepatide (PMID 40626110).
- "Ozempic face": lay term for facial volume loss with GLP-1 weight loss (PMID 37541662).
- Deoxycholic acid (Kybella): injectable approved for submental fat reduction (PMID 31860219).
- Cryolipolysis: fat reduction by cooling (PMID 40712094).
- Radiofrequency-assisted lipolysis: device category in the O'Daniel series that includes FaceTite and Morpheus8 (PMID 40712094).
- Biostimulator: injectable that stimulates collagen, such as PLLA or calcium hydroxylapatite (PMID 41127050).
- Deep cervicoplasty: neck lift that treats subplatysmal structures (PMID 40712094).
Papers
| PMID | First author | Year | Journal | Title | Finding |
|---|---|---|---|---|---|
| 40712094 | O'Daniel TG | 2026 | Aesthet Surg J | Neck Lift After Nonsurgical Treatments: Fibrosis, Fat Loss, and Surgical Complexity. | O'Daniel: prior nonsurgical neck treatment in 68%; fibrosis; deep cervicoplasty 94% |
| 42321446 | Cervantes A | 2026 | Aesthetic Plast Surg | Facelift Surgery in Patients With Prior Dermal Fillers and Energy-Based Device Treatments: Challenges and Strategic Considerations. | Facelift after fillers and energy devices, 2026 |
| 40407186 | Sharma RK | 2025 | Otolaryngol Head Neck Surg | Radiographic Midfacial Volume Changes in Patients on GLP-1 Agonists. | GLP-1: 9% midface volume loss, 7% per 10 kg |
| 40626110 | Daneshgaran G | 2025 | Aesthet Surg J Open Forum | "Ozempic Face" in Plastic Surgery: A Systematic Review of the Literature on GLP-1 Receptor Agonist Mediated Weight Loss and Analysis of Public Perceptions. | "Ozempic face" systematic review, 23 articles |
| 31860219 | Lin MJ | 2019 | J Drugs Dermatol | The Impact of Submental Deoxycholic Acid Injections on Neck Surgery. | Deoxycholic acid and later neck surgery |
| 36110395 | Alaslawi AAF | 2022 | Plast Reconstr Surg Glob Open | Facelift Surgery after Permanent Filler: Outcomes after Removal of Permanent Filler under Local Anesthesia. | Facelift with permanent filler removal, 50 patients |
| 27965217 | Jacono AA | 2017 | Aesthet Surg J | Nonsurgical Facial Rejuvenation Procedures in Patients Under 50 Prior to Undergoing Facelift: Habits, Costs, and Results. | Nonsurgical treatment habits before facelift under 50 (landmark) |
| 41988336 | Zhou X | 2026 | Front Surg | A meta-analysis of complications of thread lifting. | Thread lift complications meta-analysis, 2,827 patients |
| 37594003 | Albucker SJ | 2023 | J Cutan Med Surg | "Weekend Facelifts" Gone Wrong: Retrospective Analysis of the MAUDE Database on Thread-Lifting Complications From 2003-2023. | Thread-lift MAUDE complications 2003-2023 |
| 30882511 | Casabona G | 2019 | Dermatol Surg | Influence of Age, Sex, and Body Mass Index on the Depth of the Superficial Fascia in the Face and Neck. | Superficial fascia depth by ultrasound |
| 37541662 | Humphrey CD | 2023 | Facial Plast Surg | Implications of Ozempic and Other Semaglutide Medications for Facial Plastic Surgeons. | Ozempic implications for facial plastic surgeons |
| 38874170 | Ridha Z | 2024 | Aesthet Surg J | Decoding the Implications of Glucagon-like Peptide-1 Receptor Agonists on Accelerated Facial and Skin Aging. | GLP-1 and accelerated facial aging mechanisms |
| 42210888 | Frank K | 2026 | Dermatol Surg | GLP-1-Induced Weight Loss and the Face: Anatomical Mechanisms and Rationale for Collagen-Stimulating and Volumizing Aesthetic Treatments. | GLP-1 weight loss facial anatomy review |
| 42219269 | Chalhoub X | 2026 | Aesthet Surg J | Do GLP-1 Receptor Agonists Sabotage Fat Grafts? : A Scoping Review of GLP-1 Receptor Agonist Effects on Adipocyte Biology and Implications for Autologous Fat Transfer. | GLP-1 and fat graft biology: no outcome studies |
| 41127050 | Durairaj KK | 2025 | Aesthet Surg J Open Forum | Hyperdilute Radiesse Preserves Facial Volume in Glucagon-Like Peptide-1 Receptor Agonist Users Undergoing Rapid Weight Loss. | Hyperdilute CaHA in 4 GLP-1 users |
| 35662905 | O'Daniel TG | 2022 | Aesthet Surg J Open Forum | The Utilization of Poly-l-Lactic Acid as a Safe and Reliable Method for Volume Maintenance After Facelift Surgery With Fat Grafting. | PLLA after facelift; weight loss as indication |
| 31514808 | Couto RA | 2019 | Clin Plast Surg | Facelift in Patients with Massive Weight Loss. | Facelift after massive weight loss (landmark) |
| 30447822 | Waltzman JT | 2019 | Clin Plast Surg | Face and Neck Lifting After Weight Loss. | Face and neck lift after weight loss: modifications (landmark) |
| 39482213 | Kindel TL | 2024 | Surg Obes Relat Dis | Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. | Multisociety GLP-1 perioperative guidance 2024 |
Open questions / controversies
- No comparative study measures neck lift outcomes with and without prior nonsurgical treatment in a controlled design; data are single-surgeon (PMID 40712094).
- Fat graft survival in GLP-1 users is untested (PMID 42219269).
- Timing of facelift after GLP-1 weight loss (stable weight vs during treatment): no facelift study found in PubMed on 2026-09-25 (https://pubmed.ncbi.nlm.nih.gov/); the 2025 review calls for practice guidelines (PMID 40626110).
- Holding GLP-1 drugs before anesthesia: guidance is consensus, not evidence-based (https://www.ebi.ac.uk/europepmc/webservices/rest/PMC11666732/fullTextXML).